Univest
Univest
  • Markets

MedPlus Health Services Q1 Results FY27: What to Expect

  • June 30, 2026
  • Posted by: Ankit Jaiswal
  • Category: News
No Comments
MedPlus Health Services Q1 Results

MedPlus Health Services Q1 Results FY27: Revenue Rs 1,599 Cr (+3.6% YoY) | PAT Rs 63 Cr (+50.0% YoY). Uniresearch Q1 results preview.

This MedPlus Health Services Q1 results preview is based on Screener.in consolidated quarterly financials for the Q1 FY26 base quarter, with the Uniresearch trailing-growth model applied to project the Q1 FY27 estimate. MedPlus Health Services reported Revenue of Rs 1,543 Cr and PAT of Rs 42 Cr in Q1 FY26, forming the base for the MedPlus Health Services Q1 Results FY27 forecast of Rs 1,599 Cr Revenue and Rs 63 Cr PAT. Prepared by Ankit Jaiswal, Senior Research Analyst.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • MedPlus Health Services Q1 Results FY27: Uniresearch Prediction
  • MedPlus Health Services Q1 Results FY27 Preview: Expectations, Results Date and Latest News
  • Q4 FY26 Performance: Context for the MedPlus Health Services Q1 Results FY27 Preview
  • Uniresearch Estimate Behind the MedPlus Health Services Q1 Results FY27 Projection
  • MedPlus Health Services Q1 Results FY27 Expectations: Key Watchpoints
    • Revenue vs the Uniresearch Estimate
    • PAT Margin Sustainability
    • Management Commentary and Full-Year FY27 Guidance
  • Risks to the MedPlus Health Services Q1 Results FY27 Prediction
    • Below-Estimate Revenue Growth
    • PAT Pressure from Costs or Provisions
    • External and Macro Environment
  • MedPlus Health Services Q1 Results FY26-27: Sector Growth Drivers and Latest News
    • Occupancy and ARPOB Growth
    • Capacity Expansion
  • MedPlus Health Services Q1 Results FY27: What to Expect
  • Frequently Asked Questions on MedPlus Health Services Q1 Results FY27
    • What is the Uniresearch prediction for MedPlus Health Services Q1 Results FY27?
    • What are the MedPlus Health Services Q1 Results FY27 expectations?
    • What were the Q4 FY26 actuals behind the MedPlus Health Services Q1 Results FY27 projection?
    • How reliable is the MedPlus Health Services Q1 Results FY27 Uniresearch prediction?
    • What base data is used for the MedPlus Health Services Q1 Results FY27 Uniresearch projection?
    • What are the key risks to the MedPlus Health Services Q1 Results FY27 estimate?
    • When will MedPlus Health Services Q1 Results FY27 results be announced?

MedPlus Health Services Q1 Results FY27: Uniresearch Prediction

Metric Q1 FY26 Actual Q1 FY27 Uniresearch Prediction YoY Change
Revenue (Rs Cr) 1,543 1,599 +3.6%
PAT (Rs Cr) 42 63 +50.0%

Source: Q1 FY26 actuals from Screener.in. Q1 FY27 prediction for MedPlus Health Services applies Uniresearch trailing growth rates (Revenue +3.6%, PAT +50.0%) to Q1 FY26 verified actuals.

Track MedPlus Health Services Live on Univest Screener

MedPlus Health Services Q1 Results FY27 Preview: Expectations, Results Date and Latest News

The MedPlus Health Services Q1 results expectations for FY27 point to Revenue of Rs 1,599 Cr (+3.6% YoY) and PAT of Rs 63 Cr (+50.0% YoY), based on the MedPlus Health Services Q1 Results FY27 Uniresearch estimate. These MedPlus Health Services Q1 results expectations assume the growth trajectory from Q1 FY26 continues into Q1 FY27, supported by sector tailwinds in hospitals and diagnostics. Investors can use this MedPlus Health Services Q1 results preview as a directional reference ahead of the official result declaration.

The MedPlus Health Services Q1 results date is not yet officially announced. Typically, Q1 results dates for NSE-listed companies are disclosed via a board meeting notice on the NSE or BSE filing portal, shortly after Q1 FY27 ends. For the latest news on MedPlus Health Services Q1 results FY26-27, track the Univest Screener and NSE filing alerts. Once the MedPlus Health Services Q1 results date is confirmed, compare actual MedPlus Health Services results against this MedPlus Health Services Q1 Results FY27 preview.

Q4 FY26 Performance: Context for the MedPlus Health Services Q1 Results FY27 Preview

The MedPlus Health Services Q1 Results FY27 preview is anchored on Q4 FY26 consolidated Revenue of Rs 1,864 Cr and PAT of Rs 64 Cr. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 FY27 Uniresearch projection for MedPlus Health Services projection.

The sequential comparison also provides useful context. Q4 FY26 Revenue of Rs 1,864 Cr reflects year-end cycles that may not repeat equally in Q1 FY27. The more meaningful benchmark is the year-on-year comparison against Q1 FY26 Revenue of Rs 1,543 Cr, where the MedPlus Health Services Q1 results expectations target +3.6% growth.

Uniresearch Estimate Behind the MedPlus Health Services Q1 Results FY27 Projection

The Q1 FY27 prediction for MedPlus Health Services is derived from Uniresearch trailing analysis, which estimates Q1 FY27 Revenue growth of +3.6% and PAT growth of +50.0% YoY. These trailing rates are applied to Q1 FY26 actuals to arrive at the projection of Rs 1,599 Cr Revenue and Rs 63 Cr PAT.

The Q1 FY27 estimation methodology for MedPlus Health Services applies full-year FY27 trailing growth rates (+3.6% Revenue, +50.0% PAT) uniformly to Q1 FY26 actuals. This approach assumes the quarterly trajectory broadly mirrors the full-year trend. Treat this Q1 results preview as a directional benchmark, not a guaranteed outcome.

Get Expert Stock Picks on Univest

MedPlus Health Services Q1 Results FY27 Expectations: Key Watchpoints

Revenue vs the Uniresearch Estimate

Whether MedPlus Health Services results deliver Revenue in line with the Rs 1,599 Cr MedPlus Health Services Q1 Results FY27 Uniresearch estimate (+3.6% YoY). Q4 FY26 Revenue was Rs 1,864 Cr.

PAT Margin Sustainability

PAT of Rs 63 Cr (+50.0% YoY) is the MedPlus Health Services Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 64 Cr. Margin stability in MedPlus Health Services results signals operating leverage.

Management Commentary and Full-Year FY27 Guidance

Beyond the headline MedPlus Health Services Q1 results, management commentary will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation.

Risks to the MedPlus Health Services Q1 Results FY27 Prediction

Below-Estimate Revenue Growth

If actual MedPlus Health Services Q1 results Revenue underperforms the +3.6% growth target, the Rs 1,599 Cr MedPlus Health Services Q1 Results FY27 prediction would be revised downward.

PAT Pressure from Costs or Provisions

One-time charges, elevated provisions, or margin headwinds could push MedPlus Health Services results PAT below Rs 63 Cr in Q1 FY27.

External and Macro Environment

Macro risks including commodity price movements, rupee volatility, interest rate changes, and FII/DII sentiment shifts could create downside risk in MedPlus Health Services results even if company-specific execution remains on track.

MedPlus Health Services Q1 Results FY26-27: Sector Growth Drivers and Latest News

The latest news on MedPlus Health Services Q1 results FY26-27 from a sector perspective shows that hospitals and diagnostics is navigating the following growth drivers heading into Q1 FY27. Investors tracking MedPlus Health Services Q1 results should monitor these sector-level trends.

Occupancy and ARPOB Growth

Rising inpatient occupancy and average revenue per occupied bed are driving healthcare revenue growth.

Capacity Expansion

Brownfield bed additions and acquisitions expand capacity.

Use Univest Screener to Track MedPlus Health Services Live

MedPlus Health Services Q1 Results FY27: What to Expect

The MedPlus Health Services Q1 Results FY27 Uniresearch projection of Revenue Rs 1,599 Cr and PAT Rs 63 Cr covers the complete MedPlus Health Services Q1 results preview, including expectations, risks, and sector outlook. Track the MedPlus Health Services Q1 results date confirmation on the Univest Screener for timely updates.

Once the MedPlus Health Services results are declared, compare them against this Uniresearch preview to assess beat, meet, or miss. Access expert research and screener tools on Univest to stay updated.

Download the Univest iOS App or Univest Android App for live MedPlus Health Services Q1 FY27 result alerts.

Disclaimer: Revenue and PAT actuals sourced from Screener.in consolidated quarterly financial data. Q1 FY27 projections are derived from Uniresearch trailing growth rates applied to Q1 FY26 actuals. These are Uniresearch trailing estimates, not guaranteed outcomes. Investments are subject to market risk. For educational purposes only. SEBI RA INH000013776.

Frequently Asked Questions on MedPlus Health Services Q1 Results FY27

What is the Uniresearch prediction for MedPlus Health Services Q1 Results FY27?

Ans. Uniresearch projects Q1 FY27 Revenue for MedPlus Health Services at Rs 1,599 Cr (+3.6% YoY) and PAT at Rs 63 Cr (+50.0% YoY), based on trailing analysis of Q1 FY26 actuals (Revenue Rs 1,543 Cr, PAT Rs 42 Cr). This MedPlus Health Services Q1 Results FY27 estimate is directional, not a guaranteed outcome.

What are the MedPlus Health Services Q1 Results FY27 expectations?

Ans. The Q1 FY27 expectations for MedPlus Health Services are Revenue Rs 1,599 Cr (+3.6% YoY) and PAT Rs 63 Cr (+50.0% YoY), per the Uniresearch trailing-growth estimate. These MedPlus Health Services Q1 results expectations are based on Q1 FY26 actuals from Screener.in.

What were the Q4 FY26 actuals behind the MedPlus Health Services Q1 Results FY27 projection?

Ans. Q4 FY26 consolidated Revenue was Rs 1,864 Cr and PAT was Rs 64 Cr, serving as the most recent sequential reference for this Q1 FY27 preview of MedPlus Health Services.

How reliable is the MedPlus Health Services Q1 Results FY27 Uniresearch prediction?

Ans. The Q1 FY27 results preview for MedPlus Health Services is a Uniresearch trailing projection, not a guaranteed outcome. Actual results may differ due to macro conditions, seasonal variation, and company-specific execution. Use the projection as a directional benchmark.

What base data is used for the MedPlus Health Services Q1 Results FY27 Uniresearch projection?

Ans. The MedPlus Health Services Q1 Results FY27 projection uses Q1 FY26 consolidated actuals (Revenue Rs 1,543 Cr, PAT Rs 42 Cr) from Screener.in, with trailing growth rates (+3.6% Revenue, +50.0% PAT) applied to derive the estimate.

What are the key risks to the MedPlus Health Services Q1 Results FY27 estimate?

Ans. Key risks to the Q1 FY27 results of MedPlus\ Health\ Services include operating cost pressure, seasonal demand variation, and broader macro headwinds that could cause actual MedPlus Health Services results to undershoot the Uniresearch Q1 results preview.

When will MedPlus Health Services Q1 Results FY27 results be announced?

Ans. The MedPlus Health Services Q1 results date has not been officially announced yet. Q1 FY27 results for NSE-listed companies are typically declared shortly after Q1 FY27 ends, with the MedPlus Health Services Q1 results date disclosed via a board meeting notice on the NSE or BSE filing portal. Track the latest news on MedPlus Health Services Q1 results FY26-27 on the Univest Screener for timely updates.



News
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply